ANDAs By The Numbers: Metrics Look Good – But Review Processes Need Attention Too
Executive Summary
US FDA is approving generics at record pace, providing important statistics to support efforts by Commissioner Gottlieb to position the agency as part of the solution to concerns about high drug prices; new guidance for industry and FDA reviewers, however, suggests there is still a need for more rigor in preparing and assessing submissions.
You may also be interested in...
ANDA Complete Responses Spike In FY 2018, But Why?
In the first quarter of FY 2018, the agency issued over 800 CRs for generic drug applications, more than half the total it issued in all of FY 2017.
ANDA Complete Responses Spike In FY 2018, But Why?
In the first quarter of FY 2018, the agency issued over 800 CRs for generic drug applications, more than half the total it issued in all of FY 2017.
FDA Ends ANDA 'Reviews' To Streamline Approval Process
Instead, US agency will conduct 'assessments' of generic drug applications, according to new MaPP.